Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial

Detalles Bibliográficos
Autores principales: Snitker, Søren, Egebjerg, Christina, Frederiksen, Marie, Sparre, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805145/
https://www.ncbi.nlm.nih.gov/pubmed/35791625
http://dx.doi.org/10.1111/dom.14809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805145/
https://www.ncbi.nlm.nih.gov/pubmed/35791625
http://dx.doi.org/10.1111/dom.14809

Ejemplares similares